Investors

Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We currently have 28 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.9 billion (IQVIA, February 2018).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

"As we execute our strategy, our focus is to scale up and strengthen our business, so we can deliver sustained financial performance."

Damian Finio
CFO

Recent News

Teligent, Inc. Announces FDA Approval of Fluocinonide Gel, 0.05%

BUENA, N.J. , June 20, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...

Learn More

Teligent, Inc. Announces FDA Approval of Diflorasone Diacetate Ointment 0.05%

BUENA, N.J. , June 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...

Learn More

Teligent, Inc. Announces Closing Of $25 Million Secured Credit Facility

BUENA, N.J. , June 05, 2018 (GLOBE NEWSWIRE) -- TELIGENT, Inc. (NASDAQ:TLGT) Teligent, Inc. (“Teligent”) announced today...

Learn More

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.


Events

Investor Overview